NCT02420873 2018-08-28
An Open-label Phase II Study of Lorvotuzumab Mertansine
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
1 trialsBlastic Plasmacytoid Dendritic Cell Neoplasm × lorvotuzumab mertansine × Other hematologic neoplasm × Clear all